To contribute to healthy, fulfilling lives for people around the world, improve quality of life, and help create a prosperous future, Seikagaku Corporation is engaged in the manufacturing, research, and development of prescription pharmaceuticals. Since our founding, Seikagaku has focused on the importance of glycoscience, and as a pioneer in this emerging field, we have created innovative pharmaceuticals and medical devices.

In the fiscal year ended March 31, 2026, Seikagaku achieved two significant developments in its development pipeline.

The first was the resubmission to the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) for SI-6603, a treatment for lumbar disc herniation. Although we received notice from the FDA in March 2025 that SI-6603 was not approvable at that time, we steadily addressed the FDA’s comments and resubmitted the application in March 2026. We will make every effort to respond to the FDA’s review process so that we can provide SI-6603 in the U.S. as a new treatment option for patients suffering from leg pain associated with lumbar disc herniation.

The second was the application for marketing approval in Japan for SI-449, a surgical adhesion barrier, filed in August 2025. The review process then proceeded smoothly, and we obtained approval in April 2026. Clinical studies conducted in Japan confirmed that SI-449 offers excellent usability in laparoscopic surgery, which is now widely performed. Going forward, we will work with our sales partner to capture market share in Japan.

We would like to express our sincere appreciation for the continued understanding and support of our shareholders and other stakeholders.

June 2026
 Ken Mizutani
 President & CEO